Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Relation between Tamiflu and Sleep to Be Investigated in Clinical Study
May 28, 2007
- Daiichi Sankyo: Growing Sales of Olmesartan Offset Declining Sales of Pravastatin
May 28, 2007
- MOF Questions Insurance Coverage of OTC-Like Drugs
May 28, 2007
- Astellas: Sales Up 4.7% to \920,624 Mil. with 48.9% Overseas
May 28, 2007
- REGULATORY NEWS IN BRIEF
May 28, 2007
- Eisai: Record-High Sales with Increases in Profits 7 Years in a Row
May 28, 2007
- MEDICAL DEVICE NEWS IN BRIEF
May 28, 2007
- SURVEY／Dry Eyes Most Common Health Problem: Healthclick
May 21, 2007
- Tamiflu Jumps to Top Position: Rep Track
May 21, 2007
- Wyeth Works to Eliminate "Drug Lag" with Strong R&D Pipeline
May 21, 2007
- BUSINESS NEWS IN BRIEF
May 21, 2007
- Takeda: Strong Growth in Sales, Profits with 49.3% of Sales Overseas
May 21, 2007
- 5-Year Strategy for Innovative Drug Discovery Approved at Gov't-Private Sector Dialogue
May 21, 2007
- DSP: Combined Sales of 4 Mainstay Products Exceed \100 Bil.
May 21, 2007
- JPMA Calls For Prices Commensurate with Value during Patent Life
May 21, 2007
- MPC: Profits Up Despite 3.7% Fall in Sales
May 21, 2007
- REGULATORY NEWS IN BRIEF
May 21, 2007
- Tanabe Seiyaku: Strong Growth in Sales of Remicade Drives Business
May 21, 2007
- Latest Data from Enbrel All-Patient Surveillance Announced
May 21, 2007
- Santen: Strong Growth in Overseas Sales Drives Business
May 21, 2007
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…